Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy

There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC). We used questionnaires to evaluate the preference and reasons for drug choice between infliximab and adalimumab in UC patien...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Mizoshita, Tsutomu, Katano, Takahito, Tanida, Satoshi, Hirano, Atsuyuki, Miyaki, Tomokatsu, Ozeki, Keiji, Suzuki, Yuka, Sugimura, Naomi, Kataoka, Hiromi, Joh, Takashi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wolters Kluwer Health 2017
Gaiak:
4500
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5556246/
https://ncbi.nlm.nih.gov/pubmed/28796080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007800
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak